Alector LLC

F. Hoffmann-la Roche Ag

Angie Grace Yee

Arnon Rosenthal

Tina Schwabe

Herve Rhinn

Philip Ling Kong

Ilaria Tassi

Muhammad Abbas Alhawagri

Eric Brown

Jeonghoon Sun

Wei-Hsien Ho

Spencer Liang

Seung-Joo Lee

Marina Roell

Christoph Spiess

Hok Seon Kim

Junichiro Sonoda

Hua Long

Ananya Mitra

Karpagam Srinivasan

Santiago Viveros Salazar

Daniel P Bermingham

Francesca Cignarella

Klaus-Dieter Heger

Joanne Hongo

Diana Ronai Dunshee

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-MS4A4A antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-TMEM106B antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-MS4A6A antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.

Anti-MerTK antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Growing community of inventors

San Francisco, CA, United States of America

Angie Grace Yee